Biotech Values

[floblu14]

MNTA European/U.S. Patent Applications Update for RMF - Plus MNTA Overview of their Patent Estate -

1.N-ACETYLHEXOSAMINE-CONTAINING N-GLYCANS IN GLYCOPROTEIN PRODUCTS 2012-09-20

Abstract:
The present invention provides methods of evaluating a glycoprotein preparation for the absence, presence or amount of an N-acetylhexosamine glycan, e.g., an N- acetylglucosamine glycan.

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20120920&CC=WO&NR=2012125553A2&KC=A2

2.GLYCOSYL TRANSFERASE FROM CHINESE HAMSTER AND RELATED METHODS 2012-09-19

Abstract not available

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=1&ND=3&adjacent=true&locale=en_EP&FT=D&date=20120919&CC=EP&NR=2499245A2&KC=A2

3.EVALUATING HEPARIN PREPARATIONS 2012-08-30

Abstract:
Methods of evaluating heparin preparations, e.g., for suitability for use as a drug or for use in making a drug, by determining the absence, presence or amount of a structural signature, wherein, e.g., the structural signature is indicative of the methods used to make the heparin preparation.

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=2&ND=3&adjacent=true&locale=en_EP&FT=D&date=20120830&CC=WO&NR=2012115952A1&KC=A1

4.GLYCOSYL TRANSFERASE FROM CHINESE HAMSTER AND RELATED METHODS 2011-05-19

Abstract:
A glycosyl transferase from Chinese hamster and related methods are described.

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20110519&CC=CA&NR=2778839A1&KC=A1

5.Heparan sulfate glycosaminoglycan lyase and uses thereof
2012-04-18

Abstract:
The invention provides recombinant B. thetaiotaomicron GAG lyase polypeptides. The invention also provides nucleic acid molecules encoding such polypeptides, recombinant expression vectors containing B. thetaiotaomicron GAG lyase nucleic acid molecules, and host cells into which the expression vectors have been introduced. Characterization, diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20120418&CC=EP&NR=2441830A2&KC=A2

6.METHODS OF MODULATING FUCOSYLATION OF GLYCOPROTEINS 2012-04-11

Abstract:
Not available

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=1&ND=3&adjacent=true&locale=en_EP&FT=D&date=20120411&CC=EP&NR=2438185A1&KC=A1

7.PRODUCTION OF GLYCOPROTEINS 2012-04-04

Abstract:
Not Available

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20120404&CC=EP&NR=2435577A2&KC=A2

8.GALACTOSE-ALPHA-1, 3-GALACTOSE-CONTAINING N-GLYCANS IN GLYCOPROTEIN PRODUCTS DERIVED FROM CHO CELLS

Abstract:
The present invention provides methods for evaluating a Chinese Hamster Ovary (CHO) cell population by measuring glycans containing terminal galactose-alpha-1-3-galactose residues produced by said cells, wherein the CHO cells have not been genetically engineered to express an alpha-galactosyl transferase coding sequence.

9.Methods of evaluating mixtures of polysaccharides 2012-01-24

Abstract:
Methods for analyzing mixtures of polysaccharides, for example heparin or a LMWH, using reduce end labeling are described. In general, the mixture of polysaccharides includes polysaccharides having a desired structural moiety. In some instances, one or more polysaccharides in the mixture are chemically modified prior to analysis.

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20120124&CC=US&NR=8101733B1&KC=B1

10.Low molecular weight heparin composition and uses thereof 2012-01-11

Abstract:
Preparations of low molecular weight heparins (LMWHs) having improved properties, e.g., properties that provide a clinical advantage, are provided herein. Methods of making and using such preparations as well as methods of analyzing starting materials, processing, intermediates and final products in the production of such LMWH preparations are provided.

http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=1&ND=3&adjacent=true&locale=en_EP&FT=D&date=20111028&CC=MX&NR=2011007545A&KC=A

PATENTS

Over 100 patents give Momenta a strong proprietary position.

Momenta possesses a strong intellectual property position around our characterization platform. We license or own a total of over 100 patents and patent applications. Our patent portfolio includes claims covering:

•methods and technologies for characterizing sugars;
•the use of certain enzymes and reagents that specifically recognize polysaccharides in the characterization of sugars;
•methods and technologies for chemical and metabolic synthesis of sugars;
•the composition of matter of certain novel low-molecular-weight herapins (LMWHs), including M118, and heparinase variants;
•methods to produce and identify sugars associated with glycoproteins;
•methods to analyze and monitor glycoprotein profiles for purposes associated with the diagnosis, staging, prognosis and monitoring of cancer; and
•methods for the in vivo non-invasive delivery of sugars.

We also rely on trade secrets, know-how, continuing technological innovation and in-licensing opportunities to develop and maintain our proprietary position

http://www.momentapharma.com/technology/patents.html